

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI301002

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
Curate (ABC), LLC		06/13/2024
RECEIVING PARTY DATA		
Company Name:	Zeon Corporation	
Street Address:	1-6-2 Marunouchi	
Internal Address:	Chiyoda-ku	
City:	Tokyo	
State/Country:	JAPAN	
Postal Code:	100-8246	
PROPERTY NUMBERS Total: 63		
Property Type	Number	
Application Number:	17054097	
Application Number:	17627353	
Application Number:	17788697	
Application Number:	17793626	
Application Number:	17258716	
Application Number:	17732227	
Application Number:	18261748	
Application Number:	12037077	
Application Number:	14995894	
Application Number:	11322791	
Application Number:	17425935	
Application Number:	17671161	
Application Number:	11763421	
Application Number:	13829971	
Application Number:	13837974	
Application Number:	13835926	
Application Number:	14697372	
Application Number:	16193916	
Application Number:	12230628	

PATENT

Property Type	Number
Application Number:	16917185
Application Number:	13794503
Application Number:	13830871
Application Number:	16819992
Application Number:	17850599
Application Number:	14774268
Application Number:	17952701
Application Number:	15329753
Application Number:	15595548
Application Number:	17168081
Application Number:	16662033
Application Number:	16108365
Application Number:	17009797
Application Number:	17192691
Application Number:	17467385
Application Number:	16343754
Application Number:	17732230
Patent Number:	8021614
Patent Number:	9174222
Patent Number:	8585971
Patent Number:	9956562
Patent Number:	10786817
Patent Number:	8137912
Patent Number:	10041119
Patent Number:	10435751
Patent Number:	11261492
PCT Number:	US1931738
PCT Number:	US2042634
PCT Number:	US2066812
PCT Number:	US2113902
PCT Number:	US1941483
PCT Number:	US2015377
PCT Number:	US2159220
PCT Number:	US2213072
PCT Number:	US2281675
PCT Number:	US1648455
PCT Number:	US1847426
PCT Number:	US1757876

Property Type	Number
PCT Number:	US0612820
PCT Number:	US0636061
PCT Number:	US0771250
PCT Number:	US0771149
PCT Number:	US0771256
Application Number:	17021100

CORRESPONDENCE DATA	
Fax Number:	5616596313
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8132095010
Email:	ip@akerman.com
Correspondent Name:	Alejandro Fernandez
Address Line 1:	777 S. Flagler Drive
Address Line 2:	West Tower, Suite 1100
Address Line 4:	West Palm Beach, FLORIDA 33401

NAME OF SUBMITTER:	TOMI FATUM
SIGNATURE:	TOMI FATUM
DATE SIGNED:	06/14/2024

Total Attachments: 9 source=ASSIGNMENT FROM CURATE TO ZEON#page1.tif source=ASSIGNMENT FROM CURATE TO ZEON#page2.tif source=ASSIGNMENT FROM CURATE TO ZEON#page3.tif source=ASSIGNMENT FROM CURATE TO ZEON#page4.tif source=ASSIGNMENT FROM CURATE TO ZEON#page5.tif source=ASSIGNMENT FROM CURATE TO ZEON#page6.tif source=ASSIGNMENT FROM CURATE TO ZEON#page7.tif source=ASSIGNMENT FROM CURATE TO ZEON#page8.tif source=ASSIGNMENT FROM CURATE TO ZEON#page9.tif
--

PATENT ASSIGNMENT AGREEMENT

This PATENT ASSIGNMENT AGREEMENT ("Patent Assignment"), dated as of June 13, 2024, is made by Curate (ABC), LLC, a California limited liability company ("Seller"), in favor of Zeon Corporation ("Buyer"), a Japanese corporation, located at 1-6-2 Marunouchi, Chiyoda-ku, Tokyo 100-8246, Japan, the purchaser of certain assets of Seller pursuant to a Asset Purchase Agreement, between Buyer and Seller, dated as of June 10, 2024, (the "Asset Purchase Agreement").

WHEREAS, under the terms of the Asset Purchase Agreement, Seller has conveyed, transferred, and assigned to Buyer, among other assets, certain intellectual property of Seller, and has agreed to execute and deliver this Patent Assignment, for recording with the United States Patent and Trademark Office and corresponding entities or agencies in any applicable jurisdictions;

NOW THEREFORE, Seller agrees as follows:

1. Assignment. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller hereby irrevocably conveys, transfers, and assigns to Buyer, all of Seller's right, title, and interest in and to the following (the "Assigned Patents"):

(a) the patents and patent applications set forth in Schedule 1 hereto and all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, and renewals thereof (the "Patents");

(b) all rights of any kind whatsoever of Seller accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world;

(c) any and all royalties, fees, income, payments, and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and

(d) any and all claims and causes of action with respect to any of the foregoing, whether accruing before, on, or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, misappropriation, violation, misuse, breach, or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Recordation and Further Actions. Seller hereby authorizes the Commissioner for Patents in the United States Patent and Trademark Office and the officials of corresponding entities or agencies in any applicable jurisdictions to record and register this Patent Assignment upon request by Buyer. Following the date hereof, upon Buyer's reasonable request, Seller shall take such steps and actions, and provide such cooperation and assistance to Buyer and its successors, assigns, and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documents, as may be necessary to effect, evidence, or perfect the assignment of the Assigned Patents to Buyer, or any assignee or successor thereto.

3. Terms of the Asset Purchase Agreement. The parties hereto acknowledge and agree that this Patent Assignment is entered into pursuant to the Asset Purchase Agreement, to which reference is made for a further statement of the rights and obligations of Seller and Buyer with respect to the Assigned Patents. The representations, warranties, covenants, agreements, and indemnities contained in the Asset Purchase Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Asset Purchase Agreement and the terms hereof, the terms of the Asset Purchase Agreement shall govern.

4. Counterparts. This Patent Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed one and the same agreement. A signed copy of this Patent Assignment delivered by facsimile, e-mail, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Patent Assignment.


5. Successors and Assigns. This Patent Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

6. Governing Law. This Patent Assignment and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based upon, arising out of, or relating to this Patent Assignment and the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

[Signature Page Follows]

IN WITNESS WHEREOF, Seller has duly executed and delivered this Patent Assignment as of the date first above written.

Curate (ABC), LLC,
a California Limited Liability Company

By:  _____

Name: H. Michael Hogan

Title: Manager

Address for Notices:

231 Market Place, Suite 373

San Ramon, CA 94583


[Signature Page to Patent Assignment Agreement]

76315898;3

PATENT
REEL: 067737 FRAME: 0774

AGREED TO AND ACCEPTED:

Zeon Corporation,
a Japanese corporation

By: 
Name: Yuichiro Konishi
Title: Managing Director & Senior Corporate
Officer
Address for Notices: 1-6-2 Marunouchi,
Chiyoda-ku, Tokyo 100-8246, Japan

SCHEDULE 1

PATENTS

No.	Title	Application Number	Date of Application	Patent Number
1.	Ref 748: COMBINED PURIFICATION AND CONCENTRATION BY DETERMINISTIC LATERAL DISPLACEMENT WITH BY DETERMINISTIC LATERAL DISPLACEMENT WITH RECIRCULATION OF PRODUCT			CN 112188930B
		WO PCT/US2019/031738		
		US 17/054,097	20190510	Not issued yet
		EP 19804400.0		
		CA 3,099,717		
		AU 2023226738		
		JP 2020 563893		
		CN 202310932189		
2.	Ref 749: ORDERED PROCESSING OF BLOOD PRODUCTS TO PRODUCE THERAPEUTICALLY ACTIVE CELLS			EP 20760980.1
		WO PCT/US2020/042634		
		US 17/627,353	2020/07/17	Not issued yet
3.	Ref 750: MICROFLUIDIC CARTRIDGES FOR PROCESSING PARTICLES AND CELLS	WO PCT/US2020/066812		
		US 17/788,697	2020/12/23	Not issued yet
		EP 20842150		
		CN 202080097695		
		KR 1020227026175		
		CA 3166192		
		AU 2020411478		
		JP 2022539341		
4.	Ref 751: PREVENTION OF PLATELET ACTIVATION AND CELL DIFFERENTIATION DURING THE PROCESSING OF BLOOD AND BLOOD-RELATED COMPOSITIONS	WO PCT/US2021/013902		
		US 17/793,626	2021/01/19	Not issued yet
		EP 21745050.1		
5.	Ref 754: MICROFLUIDIC METHODS FOR THE PREPARATION OF CELLS			CN 112770840
				CA 3,106,252
				AU 2019300019
				EP 19833530.9
		WO PCT/2019/041483		
		US 17/258,716	2019/07/11	Not issued yet

		JP 2021500591		
		HK 62021034461.5		
6.	Ref 755: CELL POPULATIONS WITH IMPROVED PRODUCTION AND THERAPEUTIC CHARACTERISTICS	WO PCT/US2020/015377		
		US 17/425,935	2020/01/28	Not issued yet
		CA 3127261		
		CN 202080011399.7		
		JP 2021544203		
7.	Ref 759: METHODS FOR PRODUCING CELL POPULATIONS WITH INCREASED NUCLEIC ACID UPTAKE	WO PCT/US2021/059220		
		US 17/732,227	2022/04/28	Not issued yet
		CA 3198232		
		CN202180090610.3		
		EP 21892916.4		
		JP 2023528412		
		AU 2021378325		
8.	Ref 761: SYSTEMS AND METHODS FOR PARTICLE SEPARATION CONCENTRATION	WO PCT/US2022/013072		
		US 18/261,748	2022/1/20	Not issued yet
		CA 3,204,796		
		EP 22743149.1		
		JP 2023-543324		
		AU 2022209752		
		KR 102023702711		
		MYY PI2023004323		
9.	Ref 768: TAPERED OBSTACLE ARRAYS FOR PARTICLE PROCESSING	CN 202111538318.1		Not issued yet
		HK 42023067884.9		Not issued yet
10.	Ref 769: LABEL-FREE-CELL ISOLATION	WO PCT/US2022/081675		Not issued yet
11.	Ref 721: TAGGED LIGANDS FOR ENRICHMENT OF RARE ANALYTES FROM A MIXED SAMPLE	US 12/037077	2008/02/25	US 8,008,032
		US 14/995,894	2016/01/14	US 10,359,429
12.	Ref 724: DEVICES AND METHODS FOR ENRICHMENT AND ALTERATION OF CIRCULATING TUMOR CELLS AND OTHER PARTICLES	US 11/322,791	2005/12/29	US 8,921,102
				HK 1154422
				GB 2427468
				JP 200853828
13.	Ref 725:			US 8,021,614

	DEVICES AND METHOD FOR ENRICHMENT AND ALTERATION OF CELLS AND OTHER PARTICLES			US 9,174,222
				US 8,585,971
				US 9,956,562
				US 10,786,817
				WO US 2006/012820
				WO US 2006/036061
				EP 1866410
				EP 2664666
				EP 2492339
				IN 4390/CHENP/07
				CN ZL200680019886
		US 17/021,100	2020/09/15	Not issued yet
14.	Ref 726-a: METHODS FOR THE DIAGNOSIS OF FETAL ABNORMALITIES			US 8,137,912
				US 10,041,119
				US 10,435,751
				US 11,261,492
				EP 2366801
				HK 09107599.1
				HK 12102749.6
				HK 13107372.8
				WO US2007/71250
				WO US2007/71149
		US 17/671,161	2022/02/14	Not issued yet
		EP 22194250		
15.	Ref 727-a: RARE CELL ANALYSIS USING SAMPLE SPLITTING AND DNA TAGS	US 11/763,421	2007/06/14	US 8,372,584
		US 13/829,971	2013/03/14	US 9,273,355
		US 13/837,974	2013/03/15	US 9,347,100
		US 13/835,926	2013/03/15	US 9,017,942
		US 14/697,372	2015/04/27	US 10,155,984
				AU 2013204127
				CA 2,655,272
				CN 200780030309.3
				EP 2024513
				EP 4108780
				EP 3424598
				HK 09107598.2
				HK 10108859.1
				WO US2007/71256
		US 16/193,916	2018/11/16	US 11,781,187

16.	Ref 727.301 FETAL CELL ANALYSIS USING SAMPLE SPLITTING	US 12/230,628	2008/09/02	US 8,168,389
17.	Ref 736.304: FETAL ANEUPLOIDY DETECTION BY SEQUENCING	US 16/917,185	2020/06/30	US 11,674,176
18.	Ref 736.611: USE OF HIGHLY PARALLEL SNP GENOTYPING FOR FETAL DIAGNOSIS	US 13/794,503	2013/03/11	US 10,704,090
19.	Ref 737: DIAGNOSIS OF FETAL ABNORMALITIES USING POLYMORPHISMS INCLUDING SHORT TANDEM REPEATS			EP 07798579.4
		US 13/830,871	2013/03/14	US 10,591,391
		US 16/819,992	2020/03/16	US 11,378,498
		US 17/850,599	2022/06/27	Not issued yet
20.	Ref 716-a: ON-CHIP MICROFLUIDIC PROCESSING OF PARTICLES	US 14/774,268	2014/03/14	11,493,428
				EP 2971287
				DE 2971287
				FR 2971287
				GB 2971287
				HK 40006693
				CN 110186835
				CN 105264127
				HK 19133067.9
		EP 3569313		
21.	Ref 716-b: METHODS AND SYSTEMS FOR PROCESSING PARTICLES	US 17/952,701	2022/09/26	Not issued yet
				EP 3174976
				DE 3174976
				GB 3174976
				CH 3174976
22.	Ref 730: METHODS AND DEVICES FOR MULTI-STEP CELL PURIFICATION AND CONCENTRATION	US 15/329,753	2015/08/03	Not issued yet
		US 15/595,548	2017/05/15	US 10,976,232
		WO PCT/US2016/048455		
		HK 18109883.1		
23.	Ref 747-a: DETERMINISTIC LATERAL DISPLACEMENT IN THE PREPARATION OF CELLS AND COMPOSITIONS FOR THERAPEUTIC USES	US 17/168,081	2021/02/04	Not issued yet
				AU 2017350739
				EP 17865812.6
		CA 3,041,522		Not issued yet
		CN 201780081343.7		Not issued yet
		JP 2022192856		Not issued yet
24.	Ref 747-b:	HK 62020001795.7		Not issued yet
		US 16/662,033	2019/10/24	US 10,988,734

	METHODS FOR PREPARING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDICS	US 16/108,365	2018/08/22	US 10,844,353
		US 17/009,797	2022/09/02	US 11,149,251
		US 17/192,691	2021/03/04	US 11,306,288
				JP 2020512450
				CN 201880056966.3
		WO PCT/US2018/047426		
		US 17/467,385	2021/09/06	Not issued yet
25.	DETERMINISTIC LATERAL DISPLACEMENT IN THE PREPARATION OF CELLS AND COMPOSITIONS FOR THERAPEUTIC USES	JP 2023122659		
		US 16/343,754	2017/10/23	N/A
		EP 3528823A4		
		CA 3041522A1		
		CN 110381961A		
		AU 2017350739B2		
		JP 2020503887A		
26.	METHODS FOR PRODUCING CELL POPULATIONS WITH INCREASED NUCLEIC ACID UPTAKE	WO 2018080997A1		
		PCT/US2017/057876		
		JP2023022241A		
		US17/732,230	2022/04/28	N/A
		AU 2021378325A1	2021/11/12	
		CA 3198232A1	2021/11/12	
		WO PCT/US2021/059220	2021/11/12	
		JP 2023550050A	2021/11/12	
		EP 4244339A1	2021/11/12	